Benefits
Supports body weight and abdominal fat management
Two 12-week randomized, double-blind, placebo-controlled trials of Sinetrol® / Sinetrol-XPur in overweight adults reported significant reductions in body weight, BMI, and abdominal fat measurements versus placebo, when used alongside basic dietary and lifestyle advice.
Helps reduce waist and hip circumference
Both pivotal Sinetrol® trials reported decreases in waist and hip circumference vs placebo over 12 weeks. The pattern is consistent with modest improvements in body composition rather than dramatic standalone weight loss.
Supports lipolysis in adipocytes
In vitro and ex vivo work shows Sinetrol® inhibits cAMP-phosphodiesterase in human adipocytes, sustaining intracellular cAMP and supporting hormone-sensitive lipase activity — the proposed mechanism underlying observed reductions in adiposity in clinical trials.
Supports favorable inflammatory and oxidative markers
Trials of Sinetrol-XPur have reported modest improvements in inflammatory and oxidative stress biomarkers in overweight adults, consistent with the antioxidant activity of citrus polyphenols at clinically used doses.
Mechanism of action
cAMP-phosphodiesterase inhibition
Citrus polyphenols in Sinetrol® inhibit cAMP-phosphodiesterase in human adipocytes, sustaining elevated intracellular cAMP, activating protein kinase A, and supporting hormone-sensitive lipase-mediated triglyceride breakdown.
Adenosine receptor modulation by caffeine
Guarana-derived caffeine antagonizes adipocyte adenosine A1 receptors, which otherwise restrain lipolysis. This synergizes with citrus polyphenols' PDE inhibition to support fatty acid release from adipose tissue.
Antioxidant polyphenol activity
Naringin, hesperidin, and anthocyanins from blood orange and grapefruit components scavenge reactive oxygen species and may help modulate inflammatory signalling in metabolic tissue, supporting broader cardiometabolic effects in overweight adults.
Clinical trials
Randomized, double-blind, placebo-controlled trial of Sinetrol-XPur (1,400 mg/day) vs placebo in healthy overweight adults over 12 weeks alongside standardized dietary advice. Outcomes: body weight, BMI, abdominal fat, metabolic markers. Industry-funded.
Healthy overweight adults; 12-week intervention.
Sinetrol-XPur significantly reduced body weight, BMI, waist circumference, and abdominal adiposity vs placebo, with modest improvements in metabolic markers. Industry funding and modest effect sizes are key contextual limitations.
Randomized, double-blind, parallel-group, placebo-controlled trial of Sinetrol-XPur (900 mg/day) vs placebo in 90 overweight men over 12 weeks. Outcomes: body weight, abdominal fat, waist circumference, oxidative and inflammatory markers. Industry-funded.
90 overweight men; 12-week intervention.
Sinetrol-XPur supplementation produced statistically significant reductions in body weight, abdominal fat, and waist circumference vs placebo, alongside favorable shifts in selected oxidative and inflammatory biomarkers. Industry sponsorship is the main limitation.
Mechanistic study evaluating Sinetrol® citrus polyphenol blend on human body fat adipocytes ex vivo, characterizing its action on cAMP-phosphodiesterase and lipolysis.
Human adipocyte preparations; mechanistic in vitro work.
Sinetrol® inhibited cAMP-phosphodiesterase in human adipocytes, sustaining intracellular cAMP and supporting lipolysis. Foundational mechanistic rationale that the later 12-week RCTs in overweight adults were designed to test in vivo.